Neostigmine + Glycopyrrolate

DRUG5 trials

Sponsors

Merck Sharp & Dohme LLC, Seoul National University Hospital

Conditions

Neuromuscular BlockadeRecovery TimeReversal of Neuromuscular Blockade

Phase 4

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

CompletedNCT03346057

Merck Sharp & Dohme LLCReversal of Neuromuscular Blockade

Start: 2017-12-20End: 2019-09-04Updated: 2020-10-08

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

CompletedNCT03346070

Merck Sharp & Dohme LLCNeuromuscular Blockade

Start: 2018-01-01End: 2019-01-29Updated: 2021-01-28

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

CompletedNCT03351608

Merck Sharp & Dohme LLCNeuromuscular Blockade

Start: 2018-02-12End: 2020-01-28Updated: 2021-02-05

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

CompletedNCT03909165

Merck Sharp & Dohme LLCNeuromuscular Blockade

Start: 2019-07-23End: 2023-09-21Updated: 2025-07-25

Unknown Phase

Low-dose Neostigmine at TOF Ratio of 0.7 Improves Neuromuscular Recovery

CompletedNCT06745492

Seoul National University HospitalRecovery Time

Start: 2022-10-01End: 2023-08-25Updated: 2024-12-20

Related Papers

Sugammadex for Reversal of Neuromuscular Blockade in Neonates and Infants Less than 2 Years Old: Results from a Phase IV Randomized Clinical Trial

Anesthesiology2025-05-055 citations

Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study

Pediatric Anesthesia2021-12-0822 citations

A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants

BMC Anesthesiology2021-10-2814 citations

Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial.

2021-02-2716 citations

Pharmacokinetics of Sugammadex Dosed by Actual and Ideal Body Weight in Patients With Morbid Obesity Undergoing Surgery

Clinical and Translational Science2020-12-053 citations